Investors Purchase Large Volume of GoodRx Call Options (NASDAQ:GDRX)

GoodRx Holdings, Inc. (NASDAQ:GDRX) saw some unusual options trading activity on Monday. Stock investors bought 8,411 call options on the stock. This represents an increase of approximately 1,884% compared to the typical volume of 424 call options.

Wall Street Analysts Forecast Growth

Several analysts have commented on GDRX shares. Barclays dropped their target price on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. KeyCorp dropped their target price on shares of GoodRx from $7.00 to $6.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Citigroup dropped their target price on shares of GoodRx from $7.00 to $6.25 and set a “buy” rating for the company in a research report on Friday, January 10th. Mizuho began coverage on shares of GoodRx in a research report on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 price objective for the company. Finally, Morgan Stanley lowered their price objective on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 17th. Five research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $8.38.

GoodRx Stock Down 0.9 %

NASDAQ GDRX traded down $0.05 on Monday, reaching $4.77. The company had a trading volume of 295,807 shares, compared to its average volume of 1,064,454. The firm has a market capitalization of $1.82 billion, a price-to-earnings ratio of -158.83, a price-to-earnings-growth ratio of 2.46 and a beta of 1.28. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. GoodRx has a 1-year low of $4.09 and a 1-year high of $9.26. The company’s fifty day moving average is $4.67 and its 200-day moving average is $5.80.

Hedge Funds Weigh In On GoodRx

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GDRX. National Bank of Canada FI boosted its stake in shares of GoodRx by 34.9% during the 4th quarter. National Bank of Canada FI now owns 8,308 shares of the company’s stock worth $39,000 after buying an additional 2,151 shares during the last quarter. Gotham Asset Management LLC boosted its stake in shares of GoodRx by 31.0% during the 4th quarter. Gotham Asset Management LLC now owns 17,677 shares of the company’s stock worth $82,000 after buying an additional 4,182 shares during the last quarter. Gagnon Securities LLC boosted its stake in shares of GoodRx by 9.9% during the 4th quarter. Gagnon Securities LLC now owns 69,867 shares of the company’s stock worth $325,000 after buying an additional 6,266 shares during the last quarter. Swiss National Bank boosted its stake in shares of GoodRx by 4.1% during the 4th quarter. Swiss National Bank now owns 161,400 shares of the company’s stock worth $751,000 after buying an additional 6,400 shares during the last quarter. Finally, Fortem Financial Group LLC boosted its stake in shares of GoodRx by 7.2% during the 4th quarter. Fortem Financial Group LLC now owns 119,179 shares of the company’s stock worth $554,000 after buying an additional 7,996 shares during the last quarter. 63.77% of the stock is owned by institutional investors and hedge funds.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.